Shukuya t et al. j thorac oncol. 2020

Author: snqz

August undefined, 2024

WebSep 15, 2024 · 201. Cho BC, Kim DW, Bearz A et al. ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol 2024; 12: 1357–1367. WebJ. Thorac. Oncol. The Journal of Thoracic Oncology is a peer-reviewed medical journal covering research into cancer of the thorax, especially lung cancer. It was established in 2006 and is published nine times per year by Elsevier on behalf of the International Association for the Study of Lung Cancer, of which it is the official journal.

Mutational signature analysis in non-small cell lung …

WebJun 19, 2024 · @article{Shukuya2024CirculatingMA, title={Circulating MicroRNAs and Extracellular Vesicle–Containing MicroRNAs as Response Biomarkers of Anti–programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Therapy in NSCLC}, author={Takehito Shukuya and Vikas Ghai and Joseph M. Amann and Tamio Okimoto and Konstantin Shilo … WebEnter the email address you signed up with and we'll email you a reset link. francis goumain kevin macdonald

Introduction to 2024 WHO Classification of Thoracic Tumors

WebMar 1, 2024 · J Clin Oncol 36: 1405-1411, 2024 Link, Google Scholar: 7. Patil T, Smith DE, Bunn PA, et al: The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol 13: 1717-1726, 2024 Crossref, Medline, Google Scholar: 8. WebJun 4, 2024 · Peng et al. [ 1 ] reported their experience of 11 patients infected with COVID-19 after thoracic surgery in a high-volume centre in China during the pandemic. There were 205 patients admitted, including 119 cases with surgery and 86 cases without surgery. WebRead the March 1, 2024 issue. Volume 6, Number 3. This cross-sectional study uses data from the Surveillance, Epidemiology, and End Results Program to examine the extent to which insurance is associated with access to timely breast cancer diagnosis and breast … francis godfrey bkd

Journal of Thoracic Oncology - Wikipedia

Pembrolizumab in a Patient With Heavily Pre-Treated Squamous …

WebLetter to the Editor Wang et al show results that suggest the addition of tislelizumab to standard chemotherapy represents an additional treatment option as first-line treatment for patients with advanced squamous non–small-cell lung cancer (sq-NSCLC).1 However, for some variables, the results are limited by their own study design. WebSep 18, 2024 · Mazières J, Barlesi F, Filleron T, et al. Lung cancer patients with HER2 mutations treated with chemotherapy and ... GFPC 01-2024. J Thorac Oncol 2024;15: 628-636. Crossref; Web of Science; Medline; blank sheet of paper for typing onlineWebApr 12, 2024 · Journal of Clinical Oncology (JCO) is a high-impact, peer-reviewed medical journal that publishes significant clinical oncology research along with editorials, reviews, and other works that relate to the care of patients with cancer. francis grady apartments

"WebJ Thorac Oncol. 2024; 15: 899-901. View in Article Scopus (9) PubMed; Abstract; Full Text; Full Text PDF; Google Scholar; Nicholson A.G. Sauter J.L. Nowak A ... Beck J. et al. Molecular classification of neuroendocrine tumors of the thymus. J Thorac Oncol. 2024; 14: 1472 … " - Shukuya t et al. j thorac oncol. 2020

Shukuya t et al. j thorac oncol. 2020

Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer ESMO

WebSep 22, 2024 · 1. Introduction. COVID-19 is a life-threatening disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoX-2). Citation 1, Citation 2 Since the COVID-19 outbreak in China at the end of 2024 and until the 7 July 2024, the pandemic has infected more than 11 million people worldwide. Due to routine anti-cancer treatments and … WebVolume 15, Issue 10 Pages A1-A22, e159-e180, 1545-1690. (October 2024)

Did you know?

WebMay 2, 2024 · J Thorac Oncol. 2011;6:1242–6. Article PubMed Google Scholar Hamada T, Yasunaga H, Nakai Y, Isayama H, Matsui H, Fushimi K, Koike K . Interstitial lung disease ... M., Shukuya, T. et al. Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control ... WebNov 24, 2024 · Shukuya T, Carbone DP. Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer. J Thorac Oncol. 2016;11:976–88. Article Google Scholar Schoenfeld AJ, Rizvi H, Bandlamudi C ... Kamping EJ, von Rhein D, Jansen EAM, Hermsen …

WebJ. Thorac. Oncol. The Journal of Thoracic Oncology is a peer-reviewed medical journal covering research into cancer of the thorax, especially lung cancer. It was established in 2006 and is published nine times per year by Elsevier on behalf of the International … WebJul 27, 2024 · J Thorac Oncol 2024; 15: 448–456. Crossref. PubMed. Google Scholar. 12. ... Ko R, Shukuya T, et al. Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy. Lung ... Fukui T, Fukumoto K, …

WebJ Thorac Oncol. 2024 May;15(5):709-740. doi: 10.1016/j.jtho.2024.01.005. ... DOI: 10.1016/j.jtho.2024.01.005 Abstract Currently, there is no established guidance on how to process and evaluate resected lung cancer specimens after neoadjuvant therapy in the … WebApr 14, 2024 · The mean Ki-67 index in primary ovarian carcinoids patients was 2.5%, with a maximum of only 5%, and the prognosis was excellent. Conservative surgery, especially unilateral salpingo-oophorectomy, is...

WebOligometastatic disease has been proposed as an intermediate state between localised and systemically metastasised disease. In the absence of randomised phase 3 trials, early clinical studies show improved survival when radical local therapy is added to standard systemic therapy for oligometastatic disease. However, since no biomarker for the …

WebShukuya T, Takahashi T, Kaira R, et al. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring ... (2024). China: People’s Medical Publishing House; 2024. 10. Sun L, Guo YJ, Song J, et al. Neoadjuvant EGFR-TKI therapy for EGFR … francis gramlich obituaryWebSep 19, 2024 · Nakagiri T, Okumura M, Inoue M, et al. Thymoma-associated graft-versus-host disease-like erythroderma. J Thorac Oncol 2007; 2:1130. Eng TY, Fuller CD, Jagirdar J, et al. Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys 2004; 59:654. Lewis JE, Wick MR, Scheithauer BW, et al. Thymoma. A clinicopathologic review. Cancer … francis g. ozog funeral home incWebJul 27, 2024 · J Thorac Oncol 2024; 15: 448–456. Crossref. PubMed. Google Scholar. 12. ... Ko R, Shukuya T, et al. Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy. Lung ... Fukui T, Fukumoto K, Okasaka T, et al. Prognostic impact of tumour size in completely resected thymic ... blank sheet of paper to printWebJan 18, 2024 · Proc Am Soc Clin Oncol. 2024; 38 9500. ... J Thorac Oncol. 2007; 2: 706-714. Summary; Full Text; Full Text PDF; PubMed; ... Paz-Ares L, Ciuleanu T-E, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer ... francis granacher illinois mylifeWebJul 2, 2024 · July 2024; Authors: Jun Zhang. ... Kalla J, et al. Detection of rearrangements and tran-scriptional up-regulation of ALK in FFPE lung cancer specimens using a . ... J Thorac Oncol. 2014;9:1816 ... blank sheet of paper to draw on onlineWebOct 10, 2024 · Although Shuryak et al. have cited Arruda et al.,2 they have not paid enough attention to their very low risk estimates for LDRT at doses ≤0.5 Gy. In March 2024, when LDRT was first proposed for pneumonia associated with COVID-19,5 the initial suggested … francis grady sea isleWebJ Thorac Oncol. 2024 Oct;15(10):1657-1669. Epub 2024 Jun 26. ... Shukuya et al. 2015 (WJOG5208L) 2009-2012 Phase 3 (C) Docetaxel & Nedaplatin: Might have inferior OS Chemotherapy. Cisplatin (Platinol) 80 mg/m 2 IV once on day 1; Docetaxel (Taxotere) 60 mg/m 2 IV once on day 1; 21-day cycle for 4 to 6 cycles. blank sheet of paper to draw on